“It’s the most promising medicine to cure COVID-19” – Russia says.
MOSCOW Russia (Efe) – Avifavir is the first antiviral drug to treat COVID-19 registered by the Russian Ministry of Health after showing “great effectiveness” during clinical trials, according to the Russian Fund for Direct Investment (FRID)
The drug is based on favipiravir, which had already shown success in Japan. The Russian product is “categorically contraindicated” for pregnant women.“Avifavir is the first antiviral drug registered in Russia to treat the coronavirus and perhaps the most promising medicine to cure COVID-19 worldwide,” said FRID Director-General Kiril Dmitriev, quoted in a FRID statement.
According to the Russian official, this drug was developed and clinically tested “in record time.” It allowed it to become the first medicine based on favipiravir -antiviral developed in Japan- registered worldwide. Favipiravir, a generic antiviral, had already shown efficacy at an early stage of the disease and is marketed in Japan to treat severe influenza cases.
Avifavir, according to FRID, has shown high effectiveness in affecting the reproduction mechanisms of the coronavirus. The FRID has acknowledged that the drug is “categorically contraindicated” for pregnant women and people in the process of family planning.
Also, the FRID noted that it would not be available initially in pharmacies and “will only be used in hospitals under medical observation”.
In mid-May, Dmitriev said that 60 percent of the 40 coronavirus patients who took favipiravir tested negative for the virus within five days and indicated that the treatment could cut recovery time in half. According to data from clinical trials, the drug has high efficacy against COVID-19. The final stage of Avifavir’s clinical trials, involving 330 patients, is underway.
Russia has the second-highest number of coronavirus cases after the United States. Currently, they are testing prototype vaccines in animals, while the fund has redirected resources to produce more tests locally.
This week, the World Health Organization temporarily halted clinical trials of hydroxychloroquine in patients with COVID-19, as higher death rates were detected in patients receiving the treatment. The decision, a cautionary measure that could be reviewed, followed the publication in the medical journal The Lancet of a study indicating higher death rates.
Favipiravir is also being tested in India by Glenmark Pharmaceuticals Ltd while WHO-sponsored clinical trials are checking the antiviral drug remdesivir (commonly used against Ebola), a combination of lopinavir and ritonavir (widely used for HIV carriers), and interferon beta, a standard treatment for multiple sclerosis, in patients.
more recommended stories
Xcaret postpones the 14th edition of the Sacred Maya Journey
The return of the traditional Sacred.
A woman is crushed to death when a tree falls on top of her car on the Mérida-Valladolid highway
A strange accident happened on Thursday,.
With these local flowers, you help prevent the loss of bees in Yucatan
Every May 20, World Bee Day.
US government officials talk about UFOs publicly for the first time in 50 years
Two senior U.S. defense intelligence officials.
The US Embassy to invest 30 million USD in the “South of Mexico Generating Employment and Sustainability” program
In alliance with seven governments from.
Face-to-face courses return to La Ibérica de Mérida; they will celebrate a big event on Sunday
On Sunday, May 22, the Centro.
Construction worker arrested for sexual abuse against a maid inside a hotel in Tulum, Quintana Roo
The municipal police of Tulum, in.
Yucatan is about to receive the first cloud of dust from the Sahara desert in 2022
A cloud of dust from the.
Yucatecans seek to sell one ton of Cochinita Pibil and 6 thousand panuchos in Mexico City
With the “Yucatán Expone” program, Yucatecan.
Mérida Municipal Police officer returns wallet to owner with more than 5 thousand pesos
The Mérida Municipal Police agent Roberto.